See more : KSH Holdings Limited (ER0.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Medicure Inc. (MCUJF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medicure Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Ad-Sol Nissin Corporation (3837.T) Income Statement Analysis – Financial Results
- TransGlobe Energy Corporation (TGL.TO) Income Statement Analysis – Financial Results
- Asahi Kagaku Kogyo Co.,Ltd. (7928.T) Income Statement Analysis – Financial Results
- CSC Holdings Limited (C06.SI) Income Statement Analysis – Financial Results
- Matrix IT Ltd. (MTRX.TA) Income Statement Analysis – Financial Results
Medicure Inc. (MCUJF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medicure.com
About Medicure Inc.
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.69M | 23.07M | 21.74M | 11.61M | 20.17M | 29.11M | 27.13M | 37.78M | 22.08M | 5.05M | 2.60M | 4.80M | 3.63M | 3.32M | 4.79M | 2.25M | 5.94M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 135.87K |
| Cost of Revenue | 7.71M | 6.99M | 9.03M | 6.48M | 7.27M | 4.15M | 3.46M | 9.77M | 2.26M | 868.12K | 665.90K | 1.07M | 673.52K | 571.69K | 377.08K | 605.62K | 387.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 13.99M | 16.08M | 12.71M | 5.13M | 12.90M | 24.96M | 23.67M | 28.01M | 19.82M | 4.18M | 1.94M | 3.73M | 2.95M | 2.75M | 4.42M | 1.64M | 5.56M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 135.87K |
| Gross Profit Ratio | 64.48% | 69.69% | 58.46% | 44.19% | 63.95% | 85.74% | 87.23% | 74.14% | 89.77% | 82.81% | 74.42% | 77.71% | 81.44% | 82.77% | 92.13% | 73.05% | 93.48% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 2.41M | 2.75M | 1.80M | 3.30M | 4.35M | 6.68M | 5.15M | 5.09M | 4.87M | 688.67K | 1.70M | 1.04M | 204.69K | 393.39K | 22.71K | 28.66M | 23.34M | 10.22M | 13.56M | 4.28M | 3.12M | 3.05M | 2.48M |
| General & Administrative | 4.13M | 4.19M | 2.70M | 4.58M | 3.40M | 19.50M | 3.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.31M | 7.94M | 10.31M | 5.36M | 13.40M | 15.58M | 11.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.44M | 12.13M | 13.01M | 9.94M | 16.79M | 19.50M | 14.87M | 16.23M | 10.24M | 3.33M | 2.32M | 2.67M | 2.82M | 4.47M | 9.26M | 12.07M | 11.05M | 2.86M | 2.26M | 2.11M | 1.28M | 949.57K | 879.91K |
| Other Expenses | -854.00K | 346.00K | 1.83M | 0.00 | -3.62M | -1.47M | 82.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 898.93K | 612.52K | 372.80K | 2.65M | 2.29M | 107.38K | 57.87K | 41.01K | 33.13K | 60.51K | 12.58K |
| Operating Expenses | 13.99M | 14.88M | 14.81M | 13.24M | 21.14M | 26.18M | 20.02M | 21.33M | 15.10M | 4.02M | 4.02M | 3.72M | 3.92M | 5.48M | 9.65M | 43.39M | 36.67M | 13.18M | 15.88M | 6.43M | 4.43M | 4.06M | 3.37M |
| Cost & Expenses | 22.55M | 21.87M | 23.84M | 19.72M | 28.42M | 30.34M | 23.48M | 31.10M | 17.36M | 4.89M | 4.69M | 4.79M | 4.60M | 6.05M | 10.03M | 43.99M | 37.06M | 13.18M | 15.88M | 6.43M | 4.43M | 4.06M | 3.37M |
| Interest Income | 75.00K | 10.00K | 78.00K | 43.00K | 886.00K | 1.11M | 0.00 | 0.00 | 0.00 | 41.00 | 152.00 | 775.00 | 473.00 | 4.91K | 255.71K | 1.15M | 1.59M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 183.91K |
| Interest Expense | 10.00K | 0.00 | 38.00K | 49.00K | 22.00K | 53.68K | 90.00K | 208.64K | 367.27K | 415.84K | 418.07K | 553.73K | 3.12M | 3.28M | 4.94M | 3.83M | 1.96M | 400.87K | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.17M | 2.06M | 3.15M | 2.77M | 1.92M | 299.18K | 97.79K | 1.43M | 690.93K | 561.27K | 536.98K | 877.55K | 898.93K | 919.21K | 938.73K | 2.98M | 2.50M | 107.38K | 57.87K | 41.01K | 33.13K | 60.51K | 17.45K |
| EBITDA | 1.29M | 2.87M | 2.42M | -4.02M | -8.81M | -927.00K | 10.35M | 6.39M | 5.41M | 1.86M | -957.03K | -1.49M | -67.62K | -2.29M | -1.33M | -4.30M | -38.76M | -28.62M | -12.78M | -15.43M | -5.95M | -4.16M | -3.81M |
| EBITDA Ratio | 5.96% | 14.59% | 11.82% | -38.88% | -43.65% | -4.60% | 43.63% | 17.98% | 7.34% | -12.35% | -62.33% | 18.50% | -1.86% | -69.15% | -18.88% | -1,147.53% | -477.65% | -4,196.11% | -3,345.27% | -1,335.26% | -1,724.36% | -2,074.13% | -2,365.94% |
| Operating Income | -854.00K | 1.31M | -574.00K | -7.29M | -10.73M | -1.23M | 3.65M | 6.68M | 4.72M | 164.42K | -2.09M | 10.09K | -1.25M | -3.50M | -6.99M | -41.74M | -31.12M | -12.89M | -15.42M | -5.99M | -4.19M | -3.88M | -3.23M |
| Operating Income Ratio | -3.94% | 5.68% | -2.64% | -62.76% | -53.18% | -4.21% | 13.46% | 17.69% | 21.38% | 3.26% | -80.17% | 0.21% | -34.38% | -105.66% | -145.88% | -1,857.66% | -523.41% | -4,298.81% | -3,357.87% | -1,344.47% | -1,738.09% | -2,107.03% | -2,378.79% |
| Total Other Income/Expenses | -43.00K | 192.00K | -185.00K | 1.70M | -11.40M | 6.05M | -1.22M | -2.89M | -3.43M | 1.89M | 152.42K | -487.79K | 23.38M | -1.01M | -2.03M | 6.99M | 10.41M | 18.03M | -200.44K | -1.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -897.00K | 1.39M | -759.00K | -6.85M | -19.64M | 4.82M | 2.44M | 28.46M | 1.29M | -1.64M | -2.57M | 23.39M | -2.01M | -2.26M | -8.63M | -54.72M | -31.34M | -13.09M | -15.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -4.13% | 6.00% | -3.49% | -58.96% | -97.36% | 16.57% | 8.98% | 75.33% | 5.84% | -32.45% | -98.91% | 487.53% | -55.51% | -68.07% | -180.01% | -2,435.16% | -527.12% | -4,365.68% | -3,357.87% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 25.00K | 20.00K | -32.00K | 49.00K | 145.00K | 896.88K | -9.06M | 802.83K | -379.00K | 38.20K | -3.01K | -23.93M | -2.07M | -959.99K | 6.53M | 24.81M | -1.15M | -478.47K | -553.34K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -922.00K | 1.37M | -727.00K | -6.89M | -19.79M | 3.93M | 43.42M | 27.66M | 1.67M | -1.64M | -2.57M | 23.39M | -2.01M | -5.53M | -13.32M | -57.40M | -31.70M | -12.61M | -14.87M | -5.99M | -4.19M | -3.88M | -3.23M |
| Net Income Ratio | -4.25% | 5.92% | -3.34% | -59.38% | -98.08% | 13.49% | 160.03% | 73.21% | 7.56% | -32.45% | -98.91% | 487.53% | -55.51% | -166.79% | -277.85% | -2,554.48% | -533.30% | -4,206.05% | -3,237.37% | -1,344.47% | -1,738.09% | -2,107.03% | -2,378.79% |
| EPS | -0.09 | 0.13 | -0.07 | -0.65 | -1.32 | 0.25 | 2.78 | 1.80 | 0.12 | -0.13 | -0.21 | 1.99 | -0.23 | -0.64 | -1.53 | -6.86 | -4.53 | -2.52 | -3.34 | -1.61 | -1.69 | -2.10 | -3.00 |
| EPS Diluted | -0.09 | 0.13 | -0.07 | -0.65 | -1.32 | 0.24 | 2.39 | 1.56 | 0.11 | -0.13 | -0.21 | 1.99 | -0.23 | -0.64 | -1.53 | -6.86 | -4.53 | -2.52 | -3.34 | -1.61 | -1.67 | -2.10 | -3.00 |
| Weighted Avg Shares Out | 10.24M | 10.25M | 10.25M | 10.69M | 15.00M | 15.79M | 15.64M | 15.00M | 13.46M | 12.20M | 12.20M | 11.75M | 8.69M | 8.69M | 8.69M | 8.37M | 6.99M | 5.01M | 4.45M | 3.72M | 2.47M | 1.85M | 1.08M |
| Weighted Avg Shares Out (Dil) | 10.44M | 10.44M | 10.25M | 10.69M | 15.00M | 16.56M | 18.14M | 17.32M | 15.77M | 12.20M | 12.20M | 11.75M | 8.69M | 8.69M | 8.69M | 8.37M | 6.99M | 5.01M | 4.45M | 3.72M | 2.50M | 1.85M | 1.08M |
Medicure Reports Financial Results For Quarter Ended September 30, 2024
WINNIPEG, MB / ACCESSWIRE / November 25, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today...
Medicure to Present Financial Results on November 26, 2024 Call at 8:30 AM ET for Quarter Ended September 30, 2024 and Announces Resignation of Board Member
WINNIPEG, MB / ACCESSWIRE / November 18, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will...
Medicure Announces Positive Settlement of Product Development and Supply Contracts
WINNIPEG, MB / ACCESSWIRE / October 24, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced...
Medicure Announces Closing of Asset Purchase Agreement with Canam Bioresearch for Acquisition of Intellectual Property
WINNIPEG, MB / ACCESSWIRE / August 14, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is...
Medicure Reports Financial Results for Quarter Ended June 30, 2024
WINNIPEG, ON / ACCESSWIRE / August 14, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today...
Medicure Announces Signing of Asset Purchase Agreement with CanAm Bioresearch Inc. for Acquisition of Intellectual Property
WINNIPEG, MB / ACCESSWIRE / June 24, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today...
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
WINNIPEG, MB / ACCESSWIRE / April 23, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced...
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023
WINNIPEG, MB / ACCESSWIRE / April 8, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTCPINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported...
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
WINNIPEG, MB / ACCESSWIRE / April 4, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will...
Medicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 Diabetes
WINNIPEG, MB / ACCESSWIRE / December 5, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, through...
Source: https://incomestatements.info
Category: Stock Reports